Iron deficiency in pulmonary arterial hypertension: perspectives
نویسندگان
چکیده
In left heart failure, iron supplementation (IS) is a first-line treatment option, regardless of anemia. Pulmonary arterial hypertension (PAH), rare disease leading to right also associated with deficiency. While it much debated topic, recent evidence demonstrate that restoration stores results in improved ventricular function and exercise tolerance. Hence, IS may be considered as an option the PAH.
منابع مشابه
Iron deficiency is common in idiopathic pulmonary arterial hypertension.
The aims of this study were to assess the prevalence of iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) and investigate whether oral iron supplementation has effects in iron-deficient patients. Iron parameters were measure for all IPAH patients attending our centre (VU University Medical Center, Amsterdam, the Netherlands) between May 2009 and February 2010. Iron data were ...
متن کاملUnexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension.
BACKGROUND Anaemia is common in left heart failure and is associated with a poorer outcome. Many patients with pulmonary arterial hypertension (PAH) are anaemic or iron-deficient. This study was performed to investigate the prevalence of iron deficiency in PAH and to identify possible causes. METHODS All patients with idiopathic or heritable PAH diagnosed in 1995-2008 were identified. Control...
متن کاملIron deficiency in pulmonary arterial hypertension: a potential therapeutic target.
Iron deficiency is known to be common and detrimental in chronic left heart failure, where parenteral iron treatment has been shown to improve exercise capacity, New York Heart Association functional class and patient wellbeing. There is now increasing interest in the role of iron in the natural history of pulmonary arterial hypertension (PAH). Iron availability influences the pulmonary vasocon...
متن کاملFuture perspectives in pulmonary arterial hypertension.
While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the po...
متن کاملNovel therapeutic perspectives in pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) refers to a disease spectrum of the small pulmonary arteries leading to a progressive increase in pulmonary vascular resistance, right ventricular failure and, ultimately, death [1]. It is usually accepted that a vasoconstrictive factor is involved in PAH [2]. However, pure vasodilators, such as calcium channel blockers, have so far provided little or no be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pulmonary circulation
سال: 2021
ISSN: ['2045-8932', '2045-8940']
DOI: https://doi.org/10.1177/20458940211021301